• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Assessing asthma in adult clinical trials of inhaled B2-agonists: a search for a standard primary outcome measure 
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • Assessing asthma in adult clinical trials of inhaled B2-agonists: a search for a standard primary outcome measure
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • Assessing asthma in adult clinical trials of inhaled B2-agonists: a search for a standard primary outcome measure
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Assessing asthma in adult clinical trials of inhaled B2-agonists: a search for a standard primary outcome measure

    View/Open
    DENNISAssessingAsthma2002.pdf (9.152Mb)
    Publisher
    Queen Mary University of London
    Metadata
    Show full item record
    Abstract
    Since the late 1960s the safety of inhaled B2-agonists has been questioned and the longtenn regular use of these drugs has been linked to increasing morbidity and mortality. National and international guidelines recommend that short acting inhaled B2-agonists should only be used on an "as needed" basis and yet the evidence for these recommendations is still unclear, one reason being the lack of common definition for an outcome. The Regular Use of Salbutamol Trial (TRUST) was designed to assess the risks and benefits of regular versus as needed salbutamol in mild to moderate asthma. In order to establish whether a common primary outcome measure could improve the comparability and interpretation of different trials, a systematic rcyiew of randomised controlled trials of long and short acting inhaled B2-agonists in asthmatic subjects was undertaken to identify well designed trials in this field and primary outcome measures used. The systematic review identified five different primary outcome measures from 26 trials of long and short acting inhaled B2-agonists. The TRUST definition of exacerbation was compared with the five primary outcome measures identified using the TRUST diary card data. In addition, the diary card variables (changes in PEF, symptom scores and medication use) were examined to determine the extent to which they predicted exacerbations according to the different definitions. The use of additional corticosteroids and an increase in daytime symptoms of two or more above baseline were the strongest predictors of all four definitions of exacerbation. A fall in morning PEF of 100 lImin was strongly associated with all definitions of exacerbation but was not a sensitive measure. In conclusion, exacerbations of asthma could be identified by use of additional corticosteroids and an increase in two or more of daytime symptoms. The specificity could be improved by including morning PEF but this may reduce patient compliance with study protocol in asthma trials.
    Authors
    Dennis, Sarah M
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/1849
    Collections
    • Theses [3834]
    Copyright statements
    The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.